Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C

Digestion

Volumn 61, Issue 2, 2000, Pages 90-97

  Teuber, Gerlinde ^a   Berg, Thomas ^b   Hoffmann, Robert M ^c   Leifeldd, Ludger ^d   Lafrenz, Michael ^f   Spengler, Ulrich ^d   Pape, Gerd R ^c   Hopf, Uwe ^b   Zeuzem, Stefan ^a,e  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Medizinische Klinik   (Germany)

^e Medizinische Klinik II   (Germany)

^f NONE

Author keywords

Chronic hepatitis C; Interferon non responder; Interferon ribavirin retreatment

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SJOEGREN SYNDROME; THROMBOCYTOPENIA; VERTIGO; VOMITING;

EID: 0034003088     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007740     Document Type: Article

References (41)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PJ, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ, for the Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team: The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327: 1899-1905.
2. Di Bisceglie AM: Hepatitis C. Lancet 1998; 351:351-355.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995;332:1899-1905.
4. Saito I, Miyamura T, Ohbayashii A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87:6547-6549.
5. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 1996;24:778-789.
6. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Heathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J, and the Consensus Interferon Study Group: Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized trial. Hepatology 1997;26:747-754.
7. Kagawa T, Hosoi K, Takashimizu S, Kawazoe K, Mochizuki K, Wasada M, Nagata N, Uchiyama J, Nakano A, Nishizaki Y, Watanabe N, Matsuzaki S: Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. Am J Gastroenterol 1998; 93:192-196.
8. Zeuzem S, Lee JH, Franke A. Rüster B, Prümmer O, Herrmann G, Roth WK: Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998;27:1149-1156.
9. Reichard O, Andersson J, Schvarcz R, Weiland O: Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
10. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH: A pilot study of ribavirin therapy of chronic hepatitis C. Hepatology 1992;16:849-854.
11. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
12. Bracconier JH, Paulsen O, Engman K, Widell A: Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: A pilot study. Scand J Infect Dis 1995;27:325-329.
13. Patterson JL, Fernandez-Larsson R: Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1132-1146.
14. Sidwell R, Hoffman J, Kharp L, Allen LB, Witkowski JT, Robins RK: Broad spectrum activity of virazole: 1-beta-D-ribofuranosyl-1,2,3-triazole-3-carboxamide. Science 1972;117: 705-706.
15. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R: Lassa fever: Effective treatment with ribavirin. N Engl J Med 1986;314: 20-26.
16. Ning Q, Brown D, Parodo J, Cattral M, Gorc-zynski R, Cole E, Fung L, Liu MF, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G: Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin-1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493.
17. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
18. Reichard O, Schvarcz R, Weiland O: Therapy of hepatitis C: Alpha interferon and ribavirin. Hepatology 1997;26(suppl):108-111.
19. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavaletto L, Schvarcz R, Ideo G, Alberti A: Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997;26:961-966.
20. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O, for the Swedish Study Group: Randomised, double blind, placebo-controlled trial of interferon-α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
21. Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, for the International Hepatitis Interventional Therapy Group: Randomized trial of interferon alpha2b plus ribavirin for 48 or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
22. Brillanti S, Miglioli M, Barbara L: Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and nonresponders: Italian experience. J Hepatol 1995; 23(suppl 2):13-16.
23. Schalm SW, Brouwer JT, Chemello L, Alberti A, Bellobuono A, Ideo G., Schwartz R, Weiland O: Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1996; 41(suppl):131-134.
24. Davis GL, Esteban-Mur R, Rustigi V, Hoefs J, Gordon S, Trepo C, Schiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J, for the International Hepatitis Interventional Therapy Group: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339: 1493-1499.
25. Kakamu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y: A pilot study of ribavirin and interferon beta for the retreatment of chronic hepatitis C. Gastroenterology 1993;105:507-512.
26. Schvarcz R, Ando Y, Sönnerborg A, Weiland O: Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who failed to respond to achieve a sustained response to interferon alone: Swedish experience. J Hepatol 1995:23(suppl 2):17-21.
27. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G: Ribavirin and interteron-alpha combination therapy vs. interferon-alpha alone in the treatment of chronic hepatitis C: A randomized clinical trial. J Viral Hepat 1997;4: 185-191.
28. Desmet V, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
29. Zeuzem S, Rüster B, Roth WK: Clinical evaluation of a new polymerase chain reaction (Amplicor™ HCV) for detection of hepatitis C virus. Z Gastroenterol 1994;32:342-347.
30. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS: Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399.
31. Roth WK, Lee JH, Rüster B, Zeuzem S: Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996;34:261-264
32. Hawkins A, Davidson F, Simmonds P: Comparison of plasma virus load among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997;35:187-192.
33. Lee JH, Roth WK, Zeuzem S: Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. J Hepatol 1997; 26:1001-1009.
34. Gerken G, Teuber G, Gocrgen B, Meyer zum Büschenfelde KH: Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 1995; 22(suppl 1):118-121.
35. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G: Therapy of chronic hepatitis C: Retreatment with alpha interferon. Hepatology 1997;26(suppl 1):137-142.
36. Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, Maghinici C, Sinegre M, Benhamou JP, Degott C, Erlinger S, Marcellin P: Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998;27: 1144-1148.
37. Heathcote EJL, Keeffe EB, Lee SS, Feinmann SV, Tong MJ, Reddy KR, Albert DG, Witt K, Blatt LM, and the Consensus Interferon Study Group: Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27:1136-1143.
38. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S: Long-term histologic improvement and loss of detectable intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
39. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, Sanyal AJ, Mills AS, Garrett CT: Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785.
40. Martinol-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotava V, Benhamou JP, Erlinger S: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
41. Davis GL, Lau JYN: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122-127.